^
Association details:
Biomarker:BRAF V600M
Cancer:Melanoma
Drug:Tafinlar (dabrafenib) (BRAF inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
New
Title:

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma

Excerpt:
We present here the case of a 66 year-old male patient, diagnosed with an advanced melanoma in June 2011, and treated with Dabrafenib for double mutant metastatic disease...Mutational study of the tumor revealed a double BRAF mutation on V-600E and V600M...Almost surprisingly for the rapidity of the effect, one week later the lesion on the shoulder has reduced its size by 60% and one month later it has completely disappeared from sight.
DOI:
https://doi.org/10.1186/1756-8722-5-60